Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.
Also called NCT05669599
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 592 participants
- Sponsor
- Registry
-
NCT05669599 -
2023-510470-13-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Canada, Czechia, Germany, Hong Kong SAR China, Hungary, Japan, Poland, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05669599. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-18 (actual); primary completion 2024-10-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Biological)
- Maridebart Cafraglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct05669599- Content hash
a7f19f95aa5c61359e61b37d36b7f09679209da2a9fb595c55e1e925e636f5c0